{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-004869","form_type":"8-K","ticker":"BCRX","cik":"0000882796","company_name":"BIOCRYST PHARMACEUTICALS INC","filed_at":"2025-07-31T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.570827+00:00","generated_at":"2026-05-17T22:37:41.147204+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"BioCryst CEO Jon Stonehouse to retire Dec 31; Charlie Gayer named successor","bullets":["Jon Stonehouse retiring as CEO on Dec 31, 2025; will remain on BioCryst board.","Charlie Gayer appointed President (Aug 1, 2025) and CEO (Jan 1, 2026); previously CCO.","Gayer's base salary rises to $675k as President; expected $775k as CEO with 85% AIP target.","Gayer elected to board effective Jan 1, 2026; board size increased from nine to ten.","Stonehouse cited no disagreement; transition follows succession planning process."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-004869","json":"https://secwatch.observer/filing/0001171843-25-004869.json","markdown":"https://secwatch.observer/filing/0001171843-25-004869.md","text":"https://secwatch.observer/filing/0001171843-25-004869.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882796/000117184325004869/0001171843-25-004869-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882796/000117184325004869/f8k_073125.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T22:37:41.147204+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}